Media Library

Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.

Novartis Social Business (NSB) brings together the company’s key access-to-healthcare programs, including the Novartis Malaria Initiative, SMS for Life, Novartis Healthy Family, and Novartis Access. The 2018 NSB report provides a comprehensive overview of recent activities, and shows how these helps lower-income countries manage the dual burden of infectious and chronic diseases.

Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.

Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.

The Novartis in Society ESG Report details progress on environmental, social and governance topics and demonstrates the company’s commitment in global health and corporate responsibility.

Novartis is working on multiple fronts in the United States to build trust and expand access to healthcare in challenging times. The Novartis in Society US report details some of our initiatives in corporate responsibility, science & innovation, value & pricing, and responsible business practices.